{"id":"https://openalex.org/W2780145751","doi":"https://doi.org/10.1200/jco.2017.35.15_suppl.tps2601","title":"A phase I study to assess the safety, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activities of daily oral BAL101553, a novel tumor checkpoint controller (TCC) in adult patients with progressive or recurrent glioblastoma (GBM) or high-grade glioma.","display_name":"A phase I study to assess the safety, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activities of daily oral BAL101553, a novel tumor checkpoint controller (TCC) in adult patients with progressive or recurrent glioblastoma (GBM) or high-grade glioma.","publication_year":2017,"publication_date":"2017-05-20","ids":{"openalex":"https://openalex.org/W2780145751","doi":"https://doi.org/10.1200/jco.2017.35.15_suppl.tps2601","mag":"2780145751"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2017.35.15_suppl.tps2601","doi":"https://doi.org/10.1200/jco.2017.35.15_suppl.tps2601","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2017.35.15_suppl.tps2601","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5044949041","display_name":"Alvaro Ingles Garces","orcid":"https://orcid.org/0000-0002-0073-4237","observed_orcids":["https://orcid.org/0000-0002-0073-4237"]},"institutions":[{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]},{"id":"https://openalex.org/I4210121186","display_name":"Royal Marsden Hospital","ror":"https://ror.org/034vb5t35","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1325846038","https://openalex.org/I4210121186"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Alvaro Henrique Ingles Garces","raw_affiliation_strings":["The Royal Marsden Hospital and The Institute of Cancer Research, London, United Kingdom;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Royal Marsden Hospital and The Institute of Cancer Research, London, United Kingdom;","institution_ids":["https://openalex.org/I142947616","https://openalex.org/I4210121186"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033962986","display_name":"Elizabeth Ruth Plummer","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Elizabeth R. Plummer","raw_affiliation_strings":["Northern Centre for Cancer Care, Newcastle-upon-Tyne, United Kingdom;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Northern Centre for Cancer Care, Newcastle-upon-Tyne, United Kingdom;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064237640","display_name":"Juanita Suzanne Lopez","orcid":"https://orcid.org/0000-0001-8321-4212","observed_orcids":["https://orcid.org/0000-0001-8321-4212"]},"institutions":[{"id":"https://openalex.org/I1325846038","display_name":"Royal Marsden NHS Foundation Trust","ror":"https://ror.org/0008wzh48","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1325846038"]},{"id":"https://openalex.org/I4210121186","display_name":"Royal Marsden Hospital","ror":"https://ror.org/034vb5t35","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1325846038","https://openalex.org/I4210121186"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Juanita Suzanne Lopez","raw_affiliation_strings":["The Royal Marsden NHS Foundation Trust, London, United Kingdom;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Royal Marsden NHS Foundation Trust, London, United Kingdom;","institution_ids":["https://openalex.org/I1325846038","https://openalex.org/I4210121186"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088144652","display_name":"Rebecca Sophie Kristeleit","orcid":"https://orcid.org/0000-0003-3825-1326","observed_orcids":["https://orcid.org/0000-0003-3825-1326"]},"institutions":[{"id":"https://openalex.org/I45129253","display_name":"University College London","ror":"https://ror.org/02jx3x895","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I45129253"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Rebecca Sophie Kristeleit","raw_affiliation_strings":["University College London, London, United Kingdom;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University College London, London, United Kingdom;","institution_ids":["https://openalex.org/I45129253"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081567518","display_name":"J S Macdonald","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2800373718","display_name":"Beatson West of Scotland Cancer Centre","ror":"https://ror.org/03pp86w19","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2800373718"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Julie MacDonald","raw_affiliation_strings":["Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom;","institution_ids":["https://openalex.org/I2800373718"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045766318","display_name":"Lorna Sweeting","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2800373718","display_name":"Beatson West of Scotland Cancer Centre","ror":"https://ror.org/03pp86w19","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2800373718"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Lorna Sweeting","raw_affiliation_strings":["Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom;","institution_ids":["https://openalex.org/I2800373718"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059720629","display_name":"Michael-John Devlin","orcid":"https://orcid.org/0000-0002-4481-1716","observed_orcids":["https://orcid.org/0000-0002-4481-1716"]},"institutions":[{"id":"https://openalex.org/I45129253","display_name":"University College London","ror":"https://ror.org/02jx3x895","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I45129253"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Michael-John Devlin","raw_affiliation_strings":["University College London, London, United Kingdom;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University College London, London, United Kingdom;","institution_ids":["https://openalex.org/I45129253"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060573126","display_name":"Yvette Drew","orcid":"https://orcid.org/0000-0001-6676-9224","observed_orcids":["https://orcid.org/0000-0001-6676-9224"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yvette Drew","raw_affiliation_strings":["Northern Centre for Cancer Care, Newcastle-upon-Tyne, United Kingdom;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Northern Centre for Cancer Care, Newcastle-upon-Tyne, United Kingdom;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089364285","display_name":"Alison L. Hannah","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Alison L. Hannah","raw_affiliation_strings":["Oncology Clinical Trial Consulting, Sebastopol, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology Clinical Trial Consulting, Sebastopol, CA;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084595779","display_name":"Nicola Aceto","orcid":"https://orcid.org/0000-0001-9579-6918","observed_orcids":["https://orcid.org/0000-0001-9579-6918"]},"institutions":[{"id":"https://openalex.org/I1850255","display_name":"University of Basel","ror":"https://ror.org/02s6k3f65","country_code":"CH","type":"education","lineage":["https://openalex.org/I1850255"]},{"id":"https://openalex.org/I2802542264","display_name":"University Hospital of Basel","ror":"https://ror.org/04k51q396","country_code":"CH","type":"healthcare","lineage":["https://openalex.org/I2802542264"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Nicola Aceto","raw_affiliation_strings":["University of Basel and University Hospital Basel, Basel, Switzerland;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Basel and University Hospital Basel, Basel, Switzerland;","institution_ids":["https://openalex.org/I1850255","https://openalex.org/I2802542264"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057841016","display_name":"Stephanie Anderson","orcid":"https://orcid.org/0000-0001-9304-6419","observed_orcids":["https://orcid.org/0000-0001-9304-6419"]},"institutions":[{"id":"https://openalex.org/I4210141406","display_name":"Basilea Pharmaceutica (Switzerland)","ror":"https://ror.org/04n4q2213","country_code":"CH","type":"company","lineage":["https://openalex.org/I4210141406"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Stephanie Anderson","raw_affiliation_strings":["Basilea Pharmaceutica International Ltd, Basel, Switzerland;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Basilea Pharmaceutica International Ltd, Basel, Switzerland;","institution_ids":["https://openalex.org/I4210141406"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082438939","display_name":"Heidi A. Lane","orcid":"https://orcid.org/0000-0003-4721-0411","observed_orcids":["https://orcid.org/0000-0003-4721-0411"]},"institutions":[{"id":"https://openalex.org/I4210141406","display_name":"Basilea Pharmaceutica (Switzerland)","ror":"https://ror.org/04n4q2213","country_code":"CH","type":"company","lineage":["https://openalex.org/I4210141406"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Heidi A Lane","raw_affiliation_strings":["Basilea Pharmaceutica International Ltd, Basel, Switzerland;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Basilea Pharmaceutica International Ltd, Basel, Switzerland;","institution_ids":["https://openalex.org/I4210141406"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055037319","display_name":"Patrice J. Larger","orcid":"https://orcid.org/0000-0002-4508-4741","observed_orcids":["https://orcid.org/0000-0002-4508-4741"]},"institutions":[{"id":"https://openalex.org/I4210141406","display_name":"Basilea Pharmaceutica (Switzerland)","ror":"https://ror.org/04n4q2213","country_code":"CH","type":"company","lineage":["https://openalex.org/I4210141406"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Patrice Larger","raw_affiliation_strings":["Basilea Pharmaceutica International Ltd, Basel, Switzerland;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Basilea Pharmaceutica International Ltd, Basel, Switzerland;","institution_ids":["https://openalex.org/I4210141406"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110014825","display_name":"Martina Maurer","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210141406","display_name":"Basilea Pharmaceutica (Switzerland)","ror":"https://ror.org/04n4q2213","country_code":"CH","type":"company","lineage":["https://openalex.org/I4210141406"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Martina Maurer","raw_affiliation_strings":["Basilea Pharmaceutica International Ltd, Basel, Switzerland;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Basilea Pharmaceutica International Ltd, Basel, Switzerland;","institution_ids":["https://openalex.org/I4210141406"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069633002","display_name":"Phil McKernan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210141406","display_name":"Basilea Pharmaceutica (Switzerland)","ror":"https://ror.org/04n4q2213","country_code":"CH","type":"company","lineage":["https://openalex.org/I4210141406"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Phil McKernan","raw_affiliation_strings":["Basilea Pharmaceutica International Ltd, Basel, Switzerland;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Basilea Pharmaceutica International Ltd, Basel, Switzerland;","institution_ids":["https://openalex.org/I4210141406"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044733396","display_name":"Marc Frederick Engelhardt","orcid":"https://orcid.org/0000-0003-2432-0212","observed_orcids":["https://orcid.org/0000-0003-2432-0212"]},"institutions":[{"id":"https://openalex.org/I4210141406","display_name":"Basilea Pharmaceutica (Switzerland)","ror":"https://ror.org/04n4q2213","country_code":"CH","type":"company","lineage":["https://openalex.org/I4210141406"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Marc Frederick Engelhardt","raw_affiliation_strings":["Basilea Pharmaceutica International Ltd, Basel, Switzerland;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Basilea Pharmaceutica International Ltd, Basel, Switzerland;","institution_ids":["https://openalex.org/I4210141406"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018478201","display_name":"Alastair Greystoke","orcid":"https://orcid.org/0000-0001-9168-0387","observed_orcids":["https://orcid.org/0000-0001-9168-0387"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Alastair Greystoke","raw_affiliation_strings":["Northern Centre for Cancer Care, Newcastle-upon-Tyne, United Kingdom;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Northern Centre for Cancer Care, Newcastle-upon-Tyne, United Kingdom;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061793266","display_name":"Niamh Coleman","orcid":"https://orcid.org/0000-0002-5803-9528","observed_orcids":["https://orcid.org/0000-0002-5803-9528"]},"institutions":[{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]},{"id":"https://openalex.org/I4210121186","display_name":"Royal Marsden Hospital","ror":"https://ror.org/034vb5t35","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1325846038","https://openalex.org/I4210121186"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Niamh Coleman","raw_affiliation_strings":["The Royal Marsden Hospital and The Institute of Cancer Research, London, United Kingdom;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Royal Marsden Hospital and The Institute of Cancer Research, London, United Kingdom;","institution_ids":["https://openalex.org/I142947616","https://openalex.org/I4210121186"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014220064","display_name":"Thomas R. Jeffry Evans","orcid":"https://orcid.org/0000-0001-5201-885X","observed_orcids":["https://orcid.org/0000-0001-5201-885X"]},"institutions":[{"id":"https://openalex.org/I2800373718","display_name":"Beatson West of Scotland Cancer Centre","ror":"https://ror.org/03pp86w19","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2800373718"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"T.R. Jeffry Evans","raw_affiliation_strings":["Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom;","institution_ids":["https://openalex.org/I2800373718"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5050246084","display_name":"Paul James Mulholland","orcid":"https://orcid.org/0000-0002-7926-824X","observed_orcids":["https://orcid.org/0000-0002-7926-824X"]},"institutions":[{"id":"https://openalex.org/I45129253","display_name":"University College London","ror":"https://ror.org/02jx3x895","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I45129253"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Paul James Mulholland","raw_affiliation_strings":["University College London, London, United Kingdom;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University College London, London, United Kingdom;","institution_ids":["https://openalex.org/I45129253"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":8,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"35","issue":"15_suppl","first_page":"TPS2601","last_page":"TPS2601"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10129","display_name":"Glioma Diagnosis and Treatment","score":0.9961000084877014,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10129","display_name":"Glioma Diagnosis and Treatment","score":0.9961000084877014,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.002199999988079071,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/spindle-assembly-checkpoint","display_name":"spindle assembly checkpoint","score":0.9020000100135803},{"id":"https://openalex.org/keywords/glioblastoma","display_name":"glioblastoma","score":0.9700000286102295},{"id":"https://openalex.org/keywords/high-grade-glioma","display_name":"high-grade glioma","score":0.9700000286102295},{"id":"https://openalex.org/keywords/recurrent-glioma","display_name":"recurrent glioma","score":0.6579999923706055},{"id":"https://openalex.org/keywords/oral-prodrug","display_name":"oral prodrug","score":0.7360000014305115},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.8690000176429749},{"id":"https://openalex.org/keywords/vascular-toxicity","display_name":"vascular toxicity","score":0.6809999942779541},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8299999833106995},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.9020000100135803},{"id":"https://openalex.org/keywords/anticancer-activity","display_name":"anticancer activity","score":0.8889999985694885},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.46299999952316284},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.6119999885559082},{"id":"https://openalex.org/keywords/brain-penetration","display_name":"brain penetration","score":0.4740000069141388}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8742319941520691},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.6973875761032104},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.6537314057350159},{"id":"https://openalex.org/C108215921","wikidata":"https://www.wikidata.org/wiki/Q603741","display_name":"Prodrug","level":2,"score":0.5559739470481873},{"id":"https://openalex.org/C2778227246","wikidata":"https://www.wikidata.org/wiki/Q1365309","display_name":"Glioma","level":2,"score":0.5460678339004517},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5057179927825928},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.48477381467819214},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.4663027822971344},{"id":"https://openalex.org/C2778822529","wikidata":"https://www.wikidata.org/wiki/Q1951525","display_name":"Progressive disease","level":3,"score":0.42872291803359985},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.4168100953102112},{"id":"https://openalex.org/C509974204","wikidata":"https://www.wikidata.org/wiki/Q180507","display_name":"Radiation therapy","level":2,"score":0.41668444871902466},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4162519872188568},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.38145336508750916},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.20055460929870605}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2017.35.15_suppl.tps2601","doi":"https://doi.org/10.1200/jco.2017.35.15_suppl.tps2601","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2017.35.15_suppl.tps2601","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2947595033","https://openalex.org/W2778353074","https://openalex.org/W2742097381","https://openalex.org/W2699630253","https://openalex.org/W2891929650","https://openalex.org/W2225423293","https://openalex.org/W2891619027","https://openalex.org/W2721855883","https://openalex.org/W2399550623","https://openalex.org/W2970359173"],"abstract_inverted_index":{"TPS2601":[0],"Background:":[1],"BAL101553":[2,131,209],"(prodrug":[3],"of":[4,49,104,149,164,204,208,218,255,279],"BAL27862)":[5],"is":[6,22,176],"a":[7,23,62,186,215],"novel":[8],"TCC":[9],"that":[10,101],"promotes":[11],"tumor":[12,266,290],"cell":[13],"death":[14],"by":[15,108,119,253,268],"modulating":[16],"the":[17,34,147,156,191,198,297],"spindle":[18],"assembly":[19],"checkpoint.":[20],"BAL27862":[21],"lipophilic,":[24],"small":[25],"molecule":[26],"(MW":[27],"387)":[28],"shown":[29,41],"in":[30,45,54,135,210],"rats":[31],"to":[32,146,160,189,257],"penetrate":[33],"brain":[35],"(1:1":[36],"plasma":[37],"ratio)":[38],"and":[39,94,114,196,201],"has":[40],"promising":[42],"antitumor":[43,115,202],"activity":[44,116],"orthotopic":[46],"preclinical":[47],"models":[48],"GBM":[50,170,225],"as":[51],"monotherapy":[52],"or":[53,168,171,226,231],"combination":[55],"with":[56,67,166,223,229,246,250],"radiotherapy":[57],"(RT)":[58],"with/without":[59,237],"chemotherapy.":[60],"In":[61,123],"completed":[63],"Phase":[64,181],"1":[65,182],"study":[66,126,157,184],"2-h":[68],"IV":[69],"infusions":[70],"(Days":[71],"1,":[72],"8,":[73],"15,":[74],"q28d,":[75],"NCT01397929":[76],",":[77],"CDI-CS-001,":[78],"Lopez":[79],"et":[80],"al.":[81],"J":[82],"Clin":[83],"Oncol":[84],"34,":[85],"2016":[86],"suppl;":[87],"2525),":[88],"dose-limiting":[89,194],"vascular":[90,112,139],"effects":[91,103],"were":[92,141],"observed":[93,142,284],"appeared":[95],"Cmax":[96],"related.":[97],"Preclinical":[98],"data":[99],"suggest":[100],"antiproliferative":[102],"BAL101553/27862":[105],"are":[106,117,239,262,294],"driven":[107],"exposure":[109],"(AUC);":[110],"thus":[111],"toxicity":[113],"mediated":[118],"different":[120],"PK":[121,292],"drivers.":[122],"this":[124,154],"ongoing":[125,178],"(NCT02490800,":[127],"CDI-CS-002),":[128],"daily":[129,205],"oral":[130,206],"was":[132,158],"initially":[133],"examined":[134],"solid-tumor":[136],"patients;":[137],"no":[138],"toxicities":[140,195],"at":[143,214],"doses":[144],"up":[145],"MAD":[148],"30":[150],"mg":[151,220],"QD.":[152,221],"Given":[153],"absence,":[155],"amended":[159],"enroll":[161],"separate":[162],"cohorts":[163],"patients":[165,245],"progressive":[167,230],"recurrent":[169,232],"high-grade":[172,227,258],"glioma.":[173,259],"Methods:":[174],"This":[175,243],"an":[177],"multicenter,":[179],"open-label,":[180],"dose-escalation":[183],"using":[185,264],"3+3":[187],"design":[188],"determine":[190],"MTD,":[192],"characterize":[193],"assess":[197],"PK,":[199],"PD":[200,286],"activities":[203],"administration":[207],"consecutive":[211],"28-day":[212],"cycles":[213],"starting":[216],"dose":[217,274,280],"8":[219],"Patients":[222],"histologically-confirmed":[224,247],"glioma,":[228],"disease":[233],"after":[234],"prior":[235],"RT":[236],"chemotherapy,":[238],"eligible":[240],"for":[241,277],"enrollment.":[242],"includes":[244],"low-grade":[248],"glioma":[249],"unequivocal":[251],"evidence":[252],"imaging":[254],"transformation":[256],"Adverse":[260],"events":[261],"assessed":[263,295],"CTCAEv4;":[265],"response":[267],"RANO":[269],"(every":[270],"2":[271],"cycles).":[272],"The":[273],"escalation":[275],"allows":[276],"doubling":[278],"levels":[281],"depending":[282],"on":[283],"toxicities.":[285],"assessments":[287],"include":[288],"circulating":[289],"cells.":[291],"profiles":[293],"throughout":[296],"first":[298],"two":[299],"treatment":[300],"cycles.":[301],"Clinical":[302],"trial":[303],"information:":[304],"NCT02490800.":[305]},"counts_by_year":[{"year":2021,"cited_by_count":1}],"updated_date":"2026-09-22T06:50:58.402377","created_date":"2018-01-05T00:00:00"}